As coprescribing drugs for erectile dysfunction and oral organic nitrates for ischemic heart disease (IHD) surged, cardiovascular adverse events did not significantly increase, a new study finds. The ...

Phosphodiesterase 5 (PDE5) inhibitors (eg, sildenafil, tadalafil) do not appear to reduce the risk of Alzheimer disease and related dementias, according to a National Institutes of Health (NIH) study.

Erectile dysfunction drugs were associated with reduced risk of Alzheimer's disease, electronic health record (EHR) data from 270,000 men in the U.K. suggested. Over a median follow-up of about 5 ...

To date, benign diseases of the male and female lower urinary and genital tract, such as erectile dysfunction, bladder overactivity, lower urinary tract symptomatology secondary to benign prostatic ...

CHICAGO -- The two most popular medications for erectile dysfunction (ED) may confer substantial cardiovascular benefits for men with ED and concurrent heart disease, according to an analysis of a ...

LONDON--(BUSINESS WIRE)--The global phosphodiesterase (PDE) inhibitors market is expected to post a CAGR close to 6% during the period 2019-2023, according to the latest market research report by ...

Men taking phosphodiesterase type 5 (PDE5) inhibitors for erectile dysfunction (ED) have lower risks of overall MACE, cardiovascular mortality, and all-cause mortality than those not on these ...

Men with stable CAD who are being treated for erectile dysfunction (ED) have a lower risk of dying if their medication is a phosphodiesterase 5 (PDE5) inhibitor rather than alprostadil, observational ...